Search
ponesimod (Ponvory)
Indications:
- treatment of relapsing forms of multiple sclerosis, including
- clinically isolated syndrome
- relapsing-remitting disease
- active secondary progressive disease
Contraindications:
- pregnancy
- need for vaccination
Dosage:
- 20 mg PO QD
Pharmacokinetics:
- pharmacologic effects wear off in 1-2 weeks for most patients*
* shortest 12 life among sphingosine-1 phosphate receptor modulators
Monitor:
- continuous electrocardiographic monitoring for 24 hours after 1st dose (probably not necessary)
- ophthalmoscopy
- serum transaminases
- complete blood count (CBC)
Adverse effects:
- serious infections
- breathing problems
- liver problems
- hypertension
- skin cancer
- macular edema may occur
- bradycardia when 1st darting drug
Mechanism of action:
- selective modulator of sphingosine-1 phosphate receptor
- reduces circulating lymphocytes trapping them in lymph nodes, precluding the lymphocytes from entering the central nervous system & damaging myelin
General
neurologic agent
Database Correlations
PUBCHEM correlations
References
- George J
New Oral Agent Approved for Relapsing Multiple Sclerosis.
Novel S1P inhibitor has shorter half-life than others.
MedPage Today March 19, 2021
https://www.medpagetoday.com/neurology/multiplesclerosis/91718